(LFSC) F/m Emerald Life Sciences - Ratings and Ratios

The F/M Emerald Life Sciences Innovation ETF (NASDAQ: LFSC) is an actively managed exchange-traded fund (ETF) that focuses on equity securities of life science companies. These companies are selected by Emerald Mutual Fund Advisers Trust, the funds investment sub-advisor, under the oversight of the funds adviser. Under normal market conditions, the ETF allocates at least 80% of its net assets to equity securities issued by life science companies that demonstrate innovation. Life science companies typically include firms involved in biotechnology, pharmaceuticals, medical devices, and other related sectors. The funds investment strategy emphasizes companies that are driving advancements in medical research, drug development, and healthcare technologies.

Based on technical and fundamental data, the ETF is currently trading at $23.59 with an average 20-day volume of 5,345 shares. Its short-term trend indicators, such as the 20-day SMA ($25.04) and 50-day SMA ($24.83), suggest recent weakness, while the 200-day SMA ($25.16) indicates a slightly bearish trend. The ATR of 0.52 reflects moderate volatility. The funds assets under management (AUM) stand at $52.46 million, indicating a smaller, more specialized ETF. Over the next three months, the ETF is expected to face headwinds due to its current price being below key moving averages. However, if the broader healthcare sector stabilizes, the ETF could rebound toward its 200-day SMA level of $25.16. Investors should monitor the funds ability to regain its short-term moving averages as a potential signal for recovery.